Immune therapy in autoimmune encephalitis: A systematic review

Expert Review of Neurotherapeutics

Volumn 15, Issue 12, 2015, Pages 1391-1419

  Nosadini, Margherita ^a,b   Mohammad, Shekeeb S ^a   Ramanathan, Sudarshini ^a,c   Brilot, Fabienne ^a   Dale, Russell C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF PADOVA   (Italy)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

AMPAR; antibodies to neuronal cell surface antigens; Autoimmune encephalitis; Caspr2; immune therapy; LGI1; limbic encephalitis; NMDAR; treatment

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ANTIBODY; 4 AMINOBUTYRIC ACID B RECEPTOR ANTIBODY; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CONTACTIN ASSOCIATED PROTEIN 2 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL PEPTIDASE LIKE PROTEIN 6 ANTIBODY; DOPAMINE 2 RECEPTOR; GLYCINE R ANTIBODY; IGLON5 ANTIBODY; IMMUNOGLOBULIN; LEUCINE RICH GLIOMA INACTIVATED PROTEIN 1 ANTIBODY; MEMBRANE ANTIGEN; METABOTROPIC RECEPTOR 5; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; PROTEIN ANTIBODY; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

AGITATION; ALLERGIC ENCEPHALITIS; ANXIETY; ATAXIA; BRAIN DISEASE; CEREBELLAR ATAXIA; CHOREA; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; DYSARTHRIA; DYSAUTONOMIA; DYSPHAGIA; DYSTONIA; ENCEPHALOMYELITIS; EPILEPSY; FOLLOW UP; HUMAN; HYPONATREMIA; HYPOVENTILATION; IMMUNOTHERAPY; INSOMNIA; MEMORY DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; MORVAN SYNDROME; MULTIPLE SCLEROSIS; MUSCLE RIGIDITY; MYELITIS; MYELOOPTIC NEUROPATHY; MYOCLONUS; MYOKYMIA; NEUROLOGIC DISEASE; OCULOGYRIC CRISIS; OPSOCLONUS MYOCLONUS SYNDROME; OPTIC NEURITIS; PARANEOPLASTIC NEUROPATHY; PARKINSONISM; PERIPHERAL NERVE HYPEREXCITABILITY; PLASMAPHERESIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; RELAPSE; REVIEW; SEIZURE; SLEEP DISORDER; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT OUTCOME; VOCAL CORD PARALYSIS; WEIGHT REDUCTION; ENCEPHALITIS; HASHIMOTO DISEASE; RETROSPECTIVE STUDY;

ENCEPHALITIS; HASHIMOTO DISEASE; HUMANS; IMMUNOTHERAPY; RETROSPECTIVE STUDIES;

EID: 84949102985     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1115720     Document Type: Review

References (116)

1. Dalmau J, Furneaux HM, Rosenblum MK, et al. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology. 1991;41:1757-1764.
2. Voltz R, Dalmau J, Posner JB, et al. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology. 1998;51:1146-1150.
3. Sillevis Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology. 1995;45:1873-1878.
4. Lancaster E, Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8:380-390.
5. Irani SR, Gelfand JM, Al-Diwani A, et al. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol. 2014;76:168-184.
6. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25-36.
7. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71:1291-1292.
8. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65:424-434.
9. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9:776-785.
10. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channelcomplex proteins leucine-rich, glioma inactivated 1 protein and contactinassociated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133:2734-2748.
11. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67-76.
12. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13:276-286.
13. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77:1698-1701.
14. Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135:3453-3468.
15. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73:120-128.
16. Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eyemovement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575-586.
17. Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann N Y Acad Sci. 2015;1338:94-114.
18. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091-1098.
19. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866-5875.
20. Zuliani L, Graus F, Giometto B, et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83:638-645.
21. Vincent A, Bien CG, Irani SR, et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol. 2011;10:759-772.
22. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77:179-189.
23. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604-607.
24. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142-150.
25. Hacohen Y, Absoud M, Hemingway C, et al. NMDA receptor antibodies associated with distinct white matter syndromes. Neurol Neuroimmunol Neuroinflamm. 2014;1:e2.
26. Wright S, Hacohen Y, Jacobson L, et al. N-methyl-D-aspartate receptor antibodymediated neurological disease: results of a UK-based surveillance study in children. Arch Dis Child. 2015;100:521-526.
27. Zekeridou A, Karantoni E, Viaccoz A, et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol. 2015;262:1859-1866.
28. Irani SR, Bera K, Waters P, et al. Nmethyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655-1667.
29. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157-165.
30. Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-Methyl-D-Aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis. 2012;54:899-904.
31. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74.
32. Evoli A, Spinelli P, Frisullo G, et al. Spontaneous recovery from anti-NMDAR encephalitis. J Neurol. 2012;259:1964-1966.
33. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11-18.
34. Mohammad SS, Jones H, Hong M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol. 2015 Aug 28. DOI:10.1111/dmcn.12882. [Epub ahead of print].
35. Byrne S, Walsh C, Hacohen Y, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm. 2015;2:e130.
36. Tatencloux S, Chretien P, Rogemond V, et al. Intrathecal treatment of anti-NMethyl-D-aspartate receptor encephalitis in children. Dev Med Child Neurol. 2015;57:95-99.
37. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004;127:701-712.
38. Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582-593.
39. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136:3151-3162.
40. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69:892-900.
41. Shugaiv E, Leite MI, Şehitoʇlu E, et al. Progressive encephalomyelitis with rigidity and myoclonus: a syndrome with diverse clinical features and antibody responses. Eur Neurol. 2013;69:257-262.
42. Ramdhani RA, Frucht SJ. Isolated chorea associated with LGI1 antibody. Tremor Other Hyperkinet Mov (N Y). 2014;4:1-2.
43. Gong J, Zhang Y, Wang F, et al. Frequent hemianesthesia as initial symptom of limbic encephalitis associated with LGI1 antibodies. Neurol Sci. 2015;36:1953-1955.
44. Naasan G, Irani SR, Bettcher BM, et al. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol. 2014;71:1300-1304.
45. Nilsson AC, Blaabjerg M. More evidence of a neurocardiac prodrome in anti-LGI1 encephalitis. J Neurol Sci. 2015;357:310-311.
46. Shin YW, Lee ST, Shin JW, et al. VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol. 2013;265:75-81.
47. Malter MP, Frisch C, Schoene-Bake JC, et al. Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol. 2014;261:1695-1705.
48. Irani SR, Gelfand JM, Bettcher BM, et al. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibodyassociated encephalopathy. JAMA Neurol. 2014;71:896-900.
49. Wegner F, Wilke F, Raab P, et al. Antileucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro- 2-deoxy-d-glucose positron emission tomography. BMC Neurol. 2014;14:136.
50. Brown JW, Martin PJ, Thorpe JW, et al. Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis. J Neuroimmunol. 2014;271:66-68.
51. Szots M, Marton A, Kover F, et al. Natural course of LGI1 encephalitis: 3-5 years of follow-up without immunotherapy. J Neurol Sci. 2014;343:198-202.
52. Suleiman J, Wright S, Gill D, et al. Autoantibodies to neuronal antigens in children with new-onset seizures classified according to the revised ILAE organization of seizures and epilepsies. Epilepsia. 2013;54:2091-2100.
53. Pinatel D, Hivert B, Boucraut J, et al. Inhibitory axons are targeted in hippocampal cell culture by anti-Caspr2 autoantibodies associated with limbic encephalitis. Front Cell Neurosci. 2015;9:265.
54. Sunwoo JS, Lee ST, Byun JI, et al. Clinical manifestations of patients with CASPR2 antibodies. J Neuroimmunol. 2015;281:17-22.
55. Becker EB, Zuliani L, Pettingill R, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2012;83:437-440.
56. Huda S, Wong SH, Pettingill P, et al. An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre. J Neurol. 2015;262:418-424.
57. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72:241-255.
58. Ong E, Viaccoz A, Ducray F, et al. Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies. Eur J Neurol. 2013;20:e96-7.
59. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69:303-311.
60. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol. 2010;5:S277-S280.
61. Krogias C, Hoepner R, Müller A, et al. Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab. JAMA Neurol. 2013;70:1056-1059.
62. Bassani S, Valnegri P, Beretta F, et al. The GLUR2 subunit of AMPA receptors: synaptic role. Neuroscience. 2009;158:55-61.
63. Höftberger R, Van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 2015;84:2403-2412.
64. Bataller L, Galiano R, García-Escrig M, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology. 2010;74:265-267.
65. Graus F, Boronat A, Xifró X, et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology. 2010;74:857-859.
66. Wei YC, Liu CH, Lin JJ, et al. Rapid progression and brain atrophy in anti-AMPA receptor encephalitis. J Neuroimmunol. 2013;261:129-133.
67. Dogan Onugoren M, Deuretzbacher D, Haensch CA, et al. Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry. 2015;86:965-972.
68. Elamin M, Lonergan R, Killeen RP, et al. Posterior cortical and white matter changes on MRI in anti-AMPA receptor antibody encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e118.
69. Li X, Mao YT, Wu JJ, et al. Anti-AMPA receptor encephalitis associated with thymomatous myasthenia gravis. J Neuroimmunol. 2015;281:35-37.
70. Panzer JA, Dale RC. Anti-AMPA receptor encephalitis: the family of glutamatergic autoencephalitides further expands. Neurology. 2015;84:2390-2391.
71. Tretter V, Moss SJ. GABA(A) receptor dynamics and constructing GABAergic synapses. Front Mol Neurosci. 2008;1:1-13.
72. Pettingill P, Kramer HB, Coebergh JA, et al. Antibodies to GABAA receptor α1 and γ2 subunits: clinical and serologic characterization. Neurology. 2015;84:1233-1241.
73. Steiner I, Rüegg S. Neurology. Another autoimmune encephalitis? Not yet. Neurology. 2015;84:1192-1193.
74. Ohkawa T, Satake S, Yokoi N, et al. Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci. 2014;34:8151-8163.
75. Simabukuro MM, Petit-Pedrol M, Castro LH, et al. GABAA receptor and LGI1 antibody encephalitis in a patient with thymoma. Neurol Neuroimmunol Neuroinflamm. 2015;2:e73.
76. Boronat A, Sabater L, Saiz A, et al. GABA (B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76:795-800.
77. Jeffery OJ, Lennon VA, Pittock SJ, et al. GABAB receptor autoantibody frequency in service serologic evaluation. Neurology. 2013;81:882-887.
78. Höftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology. 2013;81:1500-1506.
79. Bettler B, Kaupmann K, Mosbacher J, et al. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev. 2004;84:835-867.
80. Kim TJ, Lee ST, Shin JW, et al. Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. J Neuroimmunol. 2014;270:45-50.
81. Bourke D, Roxburgh R, Vincent A, et al. Hypoventilation in glycine-receptor antibody related progressive encephalomyelitis, rigidity and myoclonus. J Clin Neurosci. 2014;21:876-878.
82. Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137:2178-2192.
83. McKeon A, Martinez-Hernandez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol. 2013;70:44-50.
84. Alexopoulos H, Akrivou S, Dalakas MC. Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology. 2013;81:1962-1964.
85. Clardy SL, Lennon VA, Dalmau J, et al. Childhood onset of stiff-man syndrome. JAMA Neurol. 2013;70:1531-1536.
86. Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia. 2013;54:1028-1035.
87. Ekizoglu E, Tuzun E, Woodhall M, et al. Investigation of neuronal autoantibodies in two different focal epilepsy syndromes. Epilepsia. 2014;55:414-422.
88. Zuliani L, Ferlazzo E, Andrigo C, et al. Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy. Neurol Neuroimmunol Neuroinflamm. 2014;1: e16.
89. Ariño H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy. JAMA Neurol. 2014;71:1009-1016.
90. Gresa-Arribas N, Ariño H, Martínez-Hernández E, et al. Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity. PLoS One. 2015;10:e0121364.
91. Hacohen Y, Absoud M, Woodhall M, et al. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry. 2014;85:456-461.
92. Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol. 2015;72:187-193.
93. Woodhall M, Çoban A, Waters P, et al. Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci. 2013;335:221-223.
94. Turner MR, Irani SR, Leite MI, et al. Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology. 2011;77:439-443.
95. Balint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology. 2014;82:1521-1528.
96. Tobin WO, Lennon VA, Komorowski L, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797-1803.
97. Stoeck K, Carstens PO, Jarius S, et al. Prednisolone and azathioprine are effective in DPPX antibody-positive autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e86.
98. Piepgras J, Höltje M, Michel K, et al. Anti-DPPX encephalitis: pathogenic effects of antibodies on gut and brain neurons. Neurology. 2015;85:890-897.
99. Högl B, Heidbreder A, Santamaria J, et al. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385:1590.
100. Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136.
101. Von Economo C. Encephalitis lethargica. Its sequelae and treatment. Newman KO, Translator. London: Oxford University Press; 1931.
102. Dale RC, Church AJ, Surtees RA, et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain. 2004;127:21-33.
103. Dale RC, Brilot F. Autoimmune basal ganglia disorders. J Child Neurol. 2012;27:1470-1481.
104. Mohammad SS, Sinclair K, Pillai S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord. 2014;29:117-122.
105. Pathmanandavel K, Starling J, Merheb V, et al. Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children. Biol Psychiatry. 2015;77:537-547.
106. Carr I. The Ophelia syndrome: memory loss in Hodgkin's disease. Lancet. 1982;1:844-845.
107. Pfliegler G, Pósán E, Glaub D, et al. Hodgkin's disease and memory loss: another case of the Ophelia syndrome. Br J Haematol. 1990;74:232.
108. Shinohara T, Kojima H, Nakamura N, et al. Pathology of pure hippocampal sclerosis in a patient with dementia and Hodgkin's disease: the Ophelia syndrome. Neuropathology. 2005;25:353-360.
109. Olmos D, Rueda A, Jurado JM, et al. Presentation of Hodgkin's lymphoma with Ophelia syndrome. J Clin Oncol. 2007;25:1802-1803.
110. Lu YM, Jia Z, Janus C, et al. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 longterm potentiation (LTP) but normal CA3 LTP. J Neurosci. 1997;17:5196-5205.
111. Mat A, Adler H, Merwick A, et al. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology. 2013;80:1349-1350.
112. Prüss H, Rothkirch M, Kopp U, et al. Limbic encephalitis with mGluR5 antibodies and immunotherapy-responsive prosopagnosia. Neurology. 2014;83:1384-1386.
113. Juneja M, Kaur S, Mishra D, et al. Ophelia syndrome: hodgkin lymphoma with limbic encephalitis. Indian Pediatr. 2015;52:335-336.
114. Lim M, Hacohen Y, Vincent A. Autoimmune encephalopathies. Pediatr Clin North Am. 2015 Jun;62(3):667-685. DOI:10.1016/j.pcl.2015.03.011. Epub 2015 Apr 7. Review.
115. Granerod J, Cunningham R, Zuckerman M, et al. Causality in acute encephalitis: defining aetiologies. Epidemiol Infect. 2010;138:783-800.
116. Paul NL, Kleinig TJ. Therapy of paraneoplastic disorders of the CNS. Expert Rev Neurother. 2015;15:187-193.